Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03544125 · ClinicalTrials.gov registry record · Phase 1
Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer
A Phase 1 study, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03544125 is a Phase 1 study that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 3 participants.
The verdict
NCT03544125, a Phase 1 study, has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This pilot phase I trial studies whether it is feasible to conduct a detailed molecular profile of triple negative breast cancer as part of a treatment strategy that asks whether or not we can lower the chance of breast cancer growing or spreading, by treating with a combination of PARP inhibitor how well (olaparib) and immune therapy (durvalumab). Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving olaparib and durvalumab may work better in treating participants with metastatic triple negative breast cancer.
Interventions
- BIOLOGICAL Durvalumab
- DRUG Olaparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-05-03 |
| Est. Completion | 2020-11-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03544125
The ClinicalTrials.gov registry entry for NCT03544125 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Durvalumab is the first listed.
NCT03544125 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03544125 about?
NCT03544125 is a clinical study titled "Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer". This pilot phase I trial studies whether it is feasible to conduct a detailed molecular profile of triple negative breast cancer as part of a treatment strategy that asks whether or not we can lower the chance of breast cancer growing or spreading, by treating with a combination of PARP inhibitor ho...
What is the current status of trial NCT03544125?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2018-05-03. Estimated completion is 2020-11-18.
What interventions are being tested in trial NCT03544125?
The interventions under investigation include: Durvalumab (BIOLOGICAL), Olaparib (DRUG).
Who is sponsoring clinical trial NCT03544125?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.